文献类型：期刊文献

中文题名：安寐丹对慢性失眠患者血清BDNF、GFAP和Irisin的影响

英文题名：Effect of Anmeidan on Serum Levels of BDNF,GFAP,and Irisin in Patients with Chronic Insomnia

作者：杨杰[1];谭云霞[1];王平[1];刘玲[1,2];李莉[2];纪可[2];刘福贵[1];董欢欢[2];徐福平[3];卢玉俊[4];范彦博[5]

第一作者：杨杰

机构：[1]湖北中医药大学,武汉430065;[2]湖北省中医院,湖北中医药大学附属医院,湖北省中医药研究院,武汉430061;[3]广东省中医院,广州510120;[4]甘肃中医药大学附属医院,兰州730000;[5]武汉市中医医院,武汉430010

第一机构：湖北中医药大学,武汉430065

年份：2023

卷号：29

期号：16

起止页码：170

中文期刊名：中国实验方剂学杂志

外文期刊名：Chinese Journal of Experimental Traditional Medical Formulae

收录：CSTPCD;;北大核心:【北大核心2020】；CSCD:【CSCD2023_2024】；

基金：国家科技部重点研发计划项目(2018YFC1705600);湖北省自然科学基金创新发展联合基金项目(2022CFD138)。

语种：中文

中文关键词：安寐丹;慢性失眠;血清胶质纤维酸性蛋白、脑源性神经营养因子;鸢尾素

外文关键词：Anmeidan;chronic insomnia;serum glial fibrillary acidic protein;brain-derived neurotrophic factor;irisin

摘要：目的:探索安寐丹对慢性失眠患者睡眠质量及血清脑源性神经营养因子(BDNF)、胶质纤维酸性蛋白(GFAP)和鸢尾素(irisin)的影响。方法:采用多中心、随机、双盲、安慰剂对照的临床研究方法,纳人湖北武汉、广东广州、甘肃兰州三地区480例慢性失眠虚证患者,按照入组比1:1随机分为观察组和对照组,观察组予安寐丹颗粒剂口服,11g/次,3次/d,对照组予安寐丹模拟剂口服,11g/次,3次/d,两组患者人组后均给予睡眠卫生宣教。用药4周后比较两组治疗前后阿森斯失眠量表(AIS量表)评分、Spiegel量表评分、血清BDNF、GFAP、irisin水平。结果:本研究共纳入480例成人慢性失眠患者,脱落64例。最后纳入分析415例,其中观察组213例,对照组202例。两组患者年龄比较差异无统计学意义,两组患者性别分布差异无统计学差异。与治疗前比较,两组患者治疗后AIS、Spiegel量表评分均显著降低,差异有统计学意义(P<0.01),与对照组治疗后比较,观察组治疗后AIS、Spiegel量表评分显著降低,差异有统计学意义(P<0.01)。与本组治疗前比较,观察组患者血清BDNF的水平降低,但无统计学差异,血清irisin的水平较升高,血清GFAP的水平降低,差异有统计学意义(P<0.05);与对照组治疗后比较,观察组患者血清irisin水平升高,差异有统计学意义(P<0.05),血清BDNF、GFAP水平有降低趋势,但差异无统计学意义。结论:安寐丹可能通过升高慢性失眠患者血清irisin的水平,降低血清GFAP水平改善其睡眠质量。
Objective:To explore the effect of Anmeidan on the sleep quality and serum levels of brainderived neurotrophic factor(BDNF),glial fibrillary acidic protein(GFAP),and irisin in the patients with chronic insomnia.Method:A multicenter,randomized,double-blind,placebo-controlled clinical study was carried out,including 480 patients with chronic insomnia(deficiency syndrome)in Wuhan(Hubei),Guangzhou(Guangdong),and Lanzhou(Gansu).They were randomized into an observation group and a control group at a ratio of 1∶1.The observation group was orally administered with Anmeidan granules at a dose of 11 g,3 times per day,and the control group with Anmeidan simulant at a dose of 11 g,3 times per day,Both groups of patients received sleep education after enrollment.After 4 weeks of medication,the Athens insomnia scale(AIS)scores,Spiegel scale scores,and serum levels of BDNF,GFAP,and irisin were compared between the two groups as well as between before and after treatment.Result:A total of 480 adult patients with chronic insomnia were enrolled in this study,with 64 patients falled off.Finally,the 415 patients were included in the analysis,including 213 patients in the observation group and 202 patients in the control group.There was no difference in age or sex between the two groups of patients.Compared with before treatment,the treatment in both groups decreased the AIS and Spiegel scores(P<0.01).After treatment,the observation group had lower AIS and Spiegel scores than the control group(P<0.01).The treatment in the observation group slightly lowered the level of BDNF,elevated the level of irisin(P<0.05),and lowered the level of GFAP(P<0.05)in the serum.After treatment,the observation group showed higher level of irisin(P<0.05)and lower levels of BDNF and GFAP in the serum than the control group.Conclusion:Anmeidan may improve the sleep quality of patients with chronic insomnia by elevating the irisin level and lowering the GFAP level in the serum.